Skip To Main Content
Michelle Davis on Muck Rack

Michelle Davis

As seen in: MSN, MSN Philippines, The Economic Times, The Independent (UK), TIME, Yahoo News, Los Angeles Times, Al Jazeera English, Chicago Tribune, Fortune and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Michelle

Contact Michelle, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

India's Sun Pharma plots $12 billion Organon buyout for global reach

|
By Baiju Kalesh Verified, Eyk Henning Verified, Michelle Davis, Satviki Sanjay Verified
| MSN Philippines Verified
(Bloomberg) -- Sun Pharmaceutical Industries Ltd. has agreed to acquire New York-listed women's health-care company Organon & Co., expanding its global reach with one of the biggest outbound deals by an Indian company. India's largest drugmaker will pay $14 per Organon share in cash, giving the New Jersey-based company an enterprise valuation of $11.75 billion, according to a joint statement. The deal represents a 60% premium to Organon's closing price on Jan.
Open in Who Shared View Duplicates (4) Issue with article?

Sun Pharma to buy Organon in $12 billion deal as India M&A booms Microsoft Cares About Your Privacy

|
By Baiju Kalesh Verified, Michelle Davis, Eyk Henning Verified, Satviki Sanjay Verified
| MSN Philippines Verified
(Bloomberg) -- Sun Pharmaceutical Industries Ltd. agreed to acquire New York-listed women's health-care company Organon & Co., in what is likely to be one of the biggest India outbound deals on record. Sun Pharma will pay $14 per Organon share in cash, giving the company an enterprise valuation of $11.75 billion, according to a joint statement. Sun Pharma plans to fund the acquisition through a combination of cash resources and financing from banks.
Open in Who Shared View Duplicates (8) Issue with article?
|
By Michelle Davis, Ryan Gould Verified, Loren Grush Verified, Matt Day Verified, Bruce Einhorn Verified
| The Seattle Times Verified
Open in Who Shared Issue with article?
See all 552 licensed articles (621 Total)